Solifenacin succinate for the treatment of overactive bladder

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 3, 2009, Pages 345-350

  Hoffstetter, Susan ^a   Fah, Che Leong ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticholinergic; Overactive bladder; Solifenacin succinate; Tolerability

Indexed keywords

SOLIFENACIN; TOLTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDIN 3' YL 1 PHENYL 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBOXYLATE MONOSUCCINATE; QUINUCLIDIN-3'-YL-1-PHENYL-1,2,3,4-TETRAHYDROISOQUINOLINE-2-CARBOXYLATE MONOSUCCINATE; QUINUCLIDINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; MAXIMUM PLASMA CONCENTRATION; OVERACTIVE BLADDER; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; URINARY URGENCY; URINE INCONTINENCE; URINE VOLUME; XEROSTOMIA; ANIMAL; FEMALE; MALE;

ANIMALS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; URINARY BLADDER, OVERACTIVE;

EID: 65549167423     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902762866     Document Type: Review

References (27)

1. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178 (Pubitemid 34195211)
2. Cartwright R, Renganathan A, Cardozo L. Current management of Overactive Bladder. Curr Opin Obstetrics Gynecol 2008;20(5):p489-95. Lippincott, Williams, & Wilkins
3. FDA prescribing information. Revised July 2007. Glasko Smith Kline. Astellas pharma US Inc
4. Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological characteristics of a new antimuscarinic agent, Solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 2007;30(1):54-58 (Pubitemid 46066319)
5. Kobayahsi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of Solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca+2 mobilization study in monkey cells. Life Sci 2004;74(7):843-853 (Pubitemid 37501133)
6. Okutsu H, Noguchi Y, Ohtake A, et al. Effects of intravenously and orally administered Solifenacin succinate (YM905) on carbachol-induced intravesical pre3ssure and salivary secretion in mice. Biol Pharm Bull 2007;30(12):2324-2327 (Pubitemid 350223735)
7. Masunga K, Yoshida M, Inadome A, et al. Phamacological effects of Solifenacin on human isolated urinary bladder. Pharmacology 2008;82(1):43-52 (Pubitemid 351931409)
8. Kuipers M, Smulders R, Krauwinkel W, Hoon T. Open label study of the safety and pharmacokinetics of Solifenacin in subjects with hepatic impairment. J Pharmacol Sci 2006;102(4):405-412 (Pubitemid 44954600)
9. Smulders RA, Smith NN, Krauwinkel WJ, Hoon TJ. Pharmacokinetics, safety and tolerability of Solifenacin in patients with renal insufficiency. J Pharmacol Sci 2007;103(1):67-74 (Pubitemid 46175596)
10. Michel MC, Wetterauer U, Vogel M, de la Rosette JJ. Cardiovascular safety and overall tolerability of Solifenacin in routine clinical use: a 12 week, open label, post marketing surveillance study. Drug Saf 2008;31(6):505-514 (Pubitemid 351693683)
11. Swaart PJ, Krauwinkel WJ, Smulders RA, Smith NN. Pharmacokinetic effect of ketoconazole on Solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol 2006;99(1):33-36 (Pubitemid 44034392)
12. Taekema-Roelvink ME, Swart PJ, Kuipers ME, et al. Pharmacokinetic interaction of Solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double blind, placebo controlled study. Clin Ther 2005;27(9):1403-1410 (Pubitemid 41598371)
13. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-1924 (Pubitemid 39363090)
14. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-310 (Pubitemid 38253574)
15. Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006;60:1517-1518 (Pubitemid 44082287)
16. Brunton S, Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerabiltiy of once daily solifenacin succinate 5 mg. Current Med Res Opin 2005;21(1):71-80 (Pubitemid 40327507)
17. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of Solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-470 (Pubitemid 41188406)
18. Chapple CR, Fianu-Jonsson A, Indig M, et al. Treatment outcomes in the STAR study: a subanalysis of Solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007;52:1195-1203 (Pubitemid 47337035)
19. Karram M, Toglia M, Serels S, et al. urology on line journal of the societe interantionale D urologue. Treatment with Solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double blind placebo-controlled trial. 10 November 2008
20. Millard RJ, Halaska M. Efficacy of Solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin 2006;22(1):41-48 (Pubitemid 43106906)
21. Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;(4) Art. No.:CD003781. DOI: 10.1002/14651858. CD003781.pub2
22. Wagg A, Wyndaile JJ, Sieber P. Efficacy and tolerability of Solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24 (Pubitemid 43758181)
23. Tune LE. Anticholinergic effects of medication in the elderly. J Clin Psychiatry 2001;62(Suppl 21):11-14 (Pubitemid 32937572)
24. Novara G, Galfana A, Secco S, et al. A systematic review and meta analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54(4):740-764
25. Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health related quality of life outcomes following Solifenacin treatment for overactive bladder: the VESIcare Open Label Trial. Clin Ther 2006;28(11):1935-1946 (Pubitemid 46043507)
26. Garely AD, Lucente V, Vapnek J, Smith N. Solifenacin for overactive bladder with incontinence: symptom bother and health related quality of life outcomes. Ann Pharmacother 2007;41(3):391-398 (Pubitemid 46536028)
27. Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with Solifenacin. BJU Int 2005;95(1):81-85 (Pubitemid 350020875)